Pneumocystis Pneumonia Developing during Treatment of Recurrent Renal Cell Cancer with Nivolumab.
10.3904/kjm.2018.93.6.571
- Author:
Hak Ro KIM
1
;
Bhumsuk KEAM
;
Young Sik PARK
;
Miso KIM
;
Tae Min KIM
;
Dong Wan KIM
;
Dae Seog HEO
Author Information
1. Division of Hematology and Oncology, Department of Internal Medicine, Pohang Semyeong Christianity Hospital, Pohang, Korea.
- Publication Type:Case Report
- Keywords:
Nivolumab;
Pneumonia;
Pneumocystis pneumonia
- MeSH:
Aged;
Bronchoalveolar Lavage;
Carcinoma, Renal Cell*;
Chills;
Cough;
Electrons;
Glass;
Humans;
Lung;
Male;
Pneumocystis*;
Pneumonia;
Pneumonia, Pneumocystis*;
Positron-Emission Tomography and Computed Tomography;
Sputum
- From:Korean Journal of Medicine
2018;93(6):571-574
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Nivolumab is an immune checkpoint inhibitor approved for the treatment of metastatic cancers. Here, we report the case of a 65-year-old male with recurrent renal cell carcinoma. After six cycles of nivolumab treatment, positron emission tomography/computed tomography (PET/CT) was performed to evaluate the response. PET/CT revealed diffuse ground glass opacities in both lungs. He developed a cough, sputum, chills, and a febrile sense. After bronchoscopic bronchoalveolar lavage, pneumocystis pneumonia was finally diagnosed.
